Protamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion

  • Name:

    Protamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion

  • Company:
    info
  • Active Ingredients:

    Protamine sulfate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 16/12/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/11/2014
print

Print ViewKeyword Search SmPC

LEO Pharma

LEO Pharma

Company Products

Medicine NameActive Ingredients
Medicine Name Dovobet Gel Active Ingredients Betamethasone dipropionate, Calcipotriol monohydrate
Medicine Name Dovobet Ointment Active Ingredients Betamethasone dipropionate, Calcipotriol monohydrate
Medicine Name Dovonex Cream Active Ingredients Calcipotriol hydrate
Medicine Name Dovonex Ointment Active Ingredients Calcipotriol
Medicine Name Dovonex Psoriasis 50 microgram/g ointment Active Ingredients Calcipotriol
Medicine Name Enstilar Cutaneous Foam Active Ingredients Betamethasone dipropionate, Calcipotriol monohydrate
Medicine Name Fucibet Cream Active Ingredients Betamethasone Valerate, Fusidic Acid
Medicine Name Fucibet Lipid Cream Active Ingredients Betamethasone Valerate, Fusidic Acid
Medicine Name Fucidin Cream Active Ingredients Fusidic Acid
Medicine Name Fucidin H Cream Active Ingredients Fusidic Acid Hemihydrate, Hydrocortisone Acetate
Medicine Name Fucidin Ointment Active Ingredients Sodium Fusidate
Medicine Name Fucidin Suspension Active Ingredients Fusidic Acid Hemihydrate
Medicine Name Fucidin Tablets Active Ingredients Sodium Fusidate
Medicine Name innohep 10,000 IU in 0.5 ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 10,000 IU/ml Solution for Injection (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name innohep 12,000 IU in 0.6ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 14,000 IU in 0.7 ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 16,000 IU in 0.8ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 18,000 IU in 0.9ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 2,500 IU syringe (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name Innohep 20,000 IU/ml Solution for Injection (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name innohep 3,500 IU syringe (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name innohep 4,500 IU syringe (Prophylaxis and Haemodialysis) Active Ingredients Tinzaparin sodium
Medicine Name innohep 8,000 IU in 0.4ml syringe (Treatment in VTE) Active Ingredients Tinzaparin sodium
Medicine Name Kyntheum 210 mg Solution for Injection Active Ingredients Brodalumab
1 - 0 of 42 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 16 December 2019 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 3 July 2018 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 11 November 2014 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 November 2014 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2:  updated in line with current QRD template
Section 4.2: updated in line with current QRD template, editorial changes, addition of safety and efficacy information in the paediatric population.
Section 4.3: updated in line with current QRD template

Section 4.4: Special warnings and precautions for use - updated in line with current data, editorial changes.

Administration of protamine sulphate can cause anaphylactic reactions and therefore facilities for resuscitation and treatment of shock should be available.

 

Administration of protamine sulphate, particularly when given too rapidly, may cause severe hypotension.


Risk factors for hypersensitivity (including anaphylactic reactions) to protamine sulphate:

           Allergy to fish

           Previous treatment with protamine insulin, protamine sulphate or protamine chloridecompounds

           Infertility in men

           Medical history of vasectomy (e.g. sterilisation)


Therefore if protamine sulphate is administered as a lifesaving measure to a patient with any of these conditions, the patient should be treated under closer surveillance
.

Patients with known history of allergy to fish, patients who have been treated with protamine insulin, protamine sulphate or protamine chloride, infertile men and men who have had a vasectomy (e.g. sterilisation) may develop hypersensitivity (including anaphylactic reactions) to protamine sulphate and should therefore be treated with close surveillance.

 

Excessive dosage of protamine sulphate or when given in the absence of heparin or LMWH may induce prolonged the coagulation time sincebecause protamine sulphate in itself has anticoagulant activity.

 

RA rebound anticoagulant effect of heparin/LMWH with haemorrhage has been reported occasionally despite initial adequate heparin inhibition neutralisation by protamine sulphate.

This occurs more frequently in case of extra corporeal circulation in cardiovascular surgery, within 30 minutes to 18 hours after protamine sulphate administration. This rebound bleeding responds to further doses of protamine sulphate.  


Rebound bleeding may also occur when protamine sulphate is used to reverse subcutaneous heparin or LMWH, reflecting continuous release of heparin or LMWH from the subcutaneous injection sites which act as depots.

 

Patients undergoing prolonged procedures involving repeated doses of protamine sulphate should be subject to careful monitoring of clotting parameters, e.g. activated clotting time (ACT), and as thrombocytopenia due to extracorporeal circulation may be aggravated by protamine sulphate, platelet count should be monitored.


With heparin overdose, in the absence of overt haemorrhage, serious consideration should be given as to whether protamine sulphate should be used and the risk/benefit ratio should be considered for the individual patient. The relatively short half life for heparin (especially if given intravenously) and the potential risk of administering protamine sulphate must be considered in the assessment.

 

This medicinal product contains less than 1 mmol (23 mg) sodium per 5 ml, i.e. essentially ‘sodium-free’.


Section 4.6: Fertility, pregnancy and lactation - updated in line with current pharmacovigilance data and current QRD template.

Pregnancy

There are no or limited amount of data from the use of protamine sulphate in pregnant women.


Animal studies are insufficient with respect to reproductive toxicity.


Protamine
sulphate is not recommended during pregnancy and in woman of childbearing potential not using contraception, unless the clinical condition of the woman strongly requires treatment with protamine sulphate.

Pregnancy

There are no available data from the use of protamine sulphate in pregnant women.

No reproductive toxicological studies in animals have been carried out.

However, due to the necessity to treat, Protamine sulphate LEO Pharma should be used during pregnancy only when clearly necessary.


Breast-feeding

It is unknown whether protamine sulphate is excreted in human milk. A risk to the infants cannot be excluded. Breast-feeding should be discontinued during treatment with protamine sulphate.

Lactation

It is unknown whether protamine sulphate is excreted in breast milk. Due to the potential harmful effects on infants if breast fed, lactation is not recommended during treatment.


Fertility

There are no clinical or non-clinical studies with protamine sulphate regarding fertility.


Section 4.8: Undesirable effects - updated in line with current data and addition of suspected adverse reaction national reporting statement.

The frequency of adverse reactions is not known as this cannot be estimated from the available data.

The estimation of the frequency of undesirable effects is based on a pooled analysis of data from clinical trials and from spontaneous reporting.

The most serious and frequently reported adverse reactions are hypotension, pulmonary hypertension and anaphylactic reactions.

Undesirable effects are listed by MedDRA SOC.  and the individual undesirable effects are listed starting with the most frequently reported. Within each MedDRA SOCfrequency group, adverse reactions are presented in the order of decreasing seriousness.

Very common (≥1/10)
Common (≥1/100 and < 1/10)
Uncommon (≥1/1,000 and <1/100)
Rare (≥1/10,000 and <1/1,000)
Very rare (<1/10,000)
Gastrointestinal disorders

Vomiting

Immune system disorders

Anaphylactic reaction (incl. anaphylactic shock, even fatal)

Hypersensitivity


Musculoskeletal and connective tissue disorders

Back pain


Respiratory, thoracic and mediastinal disorders

Pulmonary hypertension


Vascular disorders

Hypotension (incl. blood pressure decreased)*

Haemorrhage

Gastrointestinal disorders

Rare (≥1/10,000 and <1/1,000)

Vomiting

Immune system disorders

Rare (≥1/10,000 and <1/1,000)

Anaphylactic reaction (incl. anaphylactic shock, even fatal)

Very rare (<1/10,000)

Hypersensitivity

Musculoskeletal and connective tissue disorders

Rare (≥1/10,000 and <1/1,000)

Back pain

Respiratory, thoracic and mediastinal disorders

Common (≥1/100 and < 1/10)

Pulmonary hypertension

Vascular disorders

Common (≥1/100 and < 1/10)

Hypotension (incl. blood pressure decreased)*

Rare (≥1/10,000 and <1/1,000)

Haemorrhage

*Some of the reported hypotensive events may have anaphylactic background

 

Descriptions of selected adverse reactions
Hypersensitivity including immune-mediated allergic reactions (see section 4.4 for potential risk factors).  

 

Symptoms like urticarial or other skin rashes, peripheral vasodilation, dyspnoea or angioedema have been observed and more severe reactions include bronchospasm, hypotension with cardiac and circulatory changes, loss of consciousness and cramps. Fatal anaphylactic shock has been seen after protamine administration.

 

Prolonged hypotension accompanied by bradycardia, cyanosis, stupor, syncope, loss of consciousness or transient cardiac asystole.

 

Too rapid administration may cause hypotension (transient or severe) or bradycardia and increase the risk for anaphylactic reaction.

 

Mild events such as feeling of warmth, flushing and hypotension are commonly reported following protamine sulphate administration.

Severe systemic reactions such as pulmonary hypertension, non-cardiogenic pulmonary oedema, and severe hypotension are rarely reported.

Exact incidences cannot be given:

 

Immune System Disorders:

Hypersensitivity reactions including hypotension, dyspnoea, bronchospasm, flushing, urticaria, angioedema, anaphylactic shock (see section 4.4 for potential risk factors).

 

For potential risk factors for hypersensitivity reactions, see section 4.4.

 

Vascular and Cardiac Disorders:

Prolonged hypotension, accompanied by bradycardia, cyanosis, stupor, syncope, loss of consciousness or momentary cardiac standstill.

Too rapid administration of protamine may cause severe hypotension or bradycardia.

 

Haemorrhage (see section 4.4 and section 4.9)

 

Respiratory, Thoracic and Mediastinal Disorders:

Pulmonary arterial hypertension

 

Gastrointestinal Disorders:

Nausea and Vomiting


General Disorders and Administration Site Conditions
:

Back pain, feeling of warmth

Paediatric population
The observed safety profile is similar in children and adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via  HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Section 4.9:  Overdose - editorial changes and update to treatment options in the event of overdose.

Clinical Effect of Overdose:

Overdose may cause  bleedinghaemorrhage, as protamine sulphate in itself has an weak anticoagulant effect. Furthermore, in volunteers with very high doses of protamine sulphate (800 mg/70 kg) typical signs of histamine release were observed in a dose-dependent way such as: itching, flushingperipheral vasodilation, fatigue, malaise, nausea/vomiting, headache, hyperventilation and temperature elevation.

 

Treatment of Overdose:

In the event of bleeding haemorrhage due to protamine sulphate overdose, administration of the product should be discontinued. To determine that the pProtamine sulphate is contributing to the bleeding, the heparin titration test with protamine sulphate and the determination of plasma thrombin time are commonly used in this setting. For severe haemorrhage, transfusion of whole blood or fresh frozen plasma or other intervention may also be required. Hypotensive patients may require additional intravenous fluids, oxygen, epinephrineadrenaline, dobutamine or dopamine.

Section 6.4: updated in line with current QRD template.

Section 6.6: SPC section heading updated in line with current QRD template.

Section 10: Date of revision of text updated to October 2014

Updated on 6 November 2014 PIL

Reasons for updating

  • New PIL for new product

Updated on 6 November 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Correction of spelling/typing errors

Updated on 29 December 2011 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 14 December 2010 PIL

Reasons for updating

  • Change to date of revision

Updated on 9 December 2010 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Date of revision of the text has changed from September 2010 to November 2010

Updated on 21 October 2010 PIL

Reasons for updating

  • Change to storage instructions

Updated on 5 October 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.3 - Shelf life
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2: Editorial change only
Section 4.4: Editorial change only
Section 4.5: Editorial change only
Section 5.1: Editorial change only
Section 6.3: Addition of text: 'When diluted for administration as a slow intravenous infusion the mixture should be used immediately'.
Section 9: Date updated as a result of renewal
Section 10: Date updated as a result of revision of the text

Updated on 22 February 2010 SmPC

Reasons for updating

  • Addition of legal category
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Legal Category amended to new classification 'Product subject to prescription which may not be renewed (A)'

Updated on 29 January 2008 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 29 January 2008 PIL

Reasons for updating

  • New PIL for new product